ClinicalTrials.gg
CompletedNCT02841761Updated Nov 29, 2022

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

A Phase 1 interventional study of Midalozam and Aprocitentan in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the effect of ACT-132577 on the pharmacokinetics of midazolam and 1-hydroxy midazolam and to evaluate the safety and tolerability of ACT-132577 when administered alone and in combination with midazolam.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in the local language prior to any study-mandated procedure
  • (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at screening
  • Healthy on the basis of medical history, physical examination, cardiovascular assessments and serology and laboratory tests

Exclusion criteria

Exclusion Criteria:

  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment A (Midazolam)

    Single dose of Midazolam 8 mg on Day 1

    Drug: Midalozam

  • Experimental
    Treatment B1 (ACT-132577)

    Single dose of ACT-132577 150 mg on Day 2; single dose of ACT-132577 50 mg on Day 3, Day 4, and Day 5.

    Drug: Aprocitentan

  • Experimental
    Treatment B2 (Midazolam + ACT-132577)

    Single dose of Midazolam 8 mg and single dose of ACT-132577 50 mg on Day 6

    Drug: Midalozam · Drug: Aprocitentan

Interventions

  • DrugMidalozam

    Syrup for oral use

  • Capsules for oral use

    Also known as: ACT-132577

06

What researchers measure

Primary outcomes

  1. Maximum observed plama concentration (Cmax)

    Cmax of midazolam and 1-hydroxy midazolam following administration of midazolam alone and in combination with ACT-132577

    Time frame: Midazolam PK sampling on Days 1, 2, 6 and 7

  2. Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)

    AUC0-∞ of midazolam and 1-hydroxy midazolam following administration of midazolam alone and in combination with ACT-132577

    Time frame: Midazolam PK sampling on Days 1, 2, 6 and 7

  3. Time to reach Cmax (tmax)

    Tmax of midazolam and 1-hydroxy midazolam following administration of midazolam alone and in combination with ACT-132577

    Time frame: Midazolam PK sampling on Days 1, 2, 6 and 7

  4. Terminal half-life (t1/2)

    T1/2 of midazolam and 1-hydroxy midazolam following administration of midazolam alone and in combination with ACT-132577

    Time frame: Midazolam PK sampling on Days 1, 2, 6 and 7

Secondary outcomes

  1. Number of subjects with adverse events

    Time frame: From Day 1 to Follow-up (for up to 38 days)

  2. Number of subjects with serious adverse events

    Time frame: From Screening to Follow-up (for up to 59 days)

07

Study locations

1 site
  • Investigator Site
    Newark, New Jersey 07103, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Sep 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2016
First posted
Jul 22, 2016
Start
Jul 1, 2016
Primary completionActual
Sep 1, 2016
CompletionActual
Oct 1, 2016
Last update
Nov 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02841761
Responsible party
Sponsor
First posted
Jul 22, 2016
Start date
Jul 1, 2016
Primary completion
Sep 1, 2016
Completion
Oct 1, 2016
Last update
Nov 29, 2022

Study contacts

Clinical Trial
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprocitentan

Start the discussion